Intangible Assets

IMMP lacks evidence of durable brand, proprietary IP, or regulatory exclusivity in the provided filings and metrics, so it does not appear to command peer-level pricing power.

The negative ROIC and ROCE indicate that any intangible value is not yet translating into economic returns, unlike stronger biotech peers with approved products or protected cash flows.

With no disclosed long-run margin history or recurring commercial franchise in the supplied data, intangible assets appear limited to pipeline optionality rather than a durable moat.

Compared with peers that have marketed therapies, IMMP’s intangible position is materially weaker because it has not demonstrated sustained retention or monetization of differentiated assets.

Switching Costs

The provided data show no recurring customer base, installed base, or workflow integration that would make switching costly, so retention appears low versus commercial-stage peers.

Negative profitability and extremely high cash conversion cycle are inconsistent with embedded customer dependence, which suggests buyers can substitute alternatives without material friction.

IMMP’s development-stage profile implies purchasing decisions are driven by clinical and regulatory outcomes rather than customer lock-in, unlike peers with approved therapies and reimbursement relationships.

There is no evidence in the supplied materials of contractual, technical, or clinical switching barriers that would sustain pricing power over 5–10 years.

Network Effects

The company shows no evidence of user, data, or ecosystem network effects in the provided information, so adoption by one customer does not appear to increase value for others.

Biopharma development generally does not create self-reinforcing network effects, and IMMP’s metrics do not indicate any platform-like advantage versus peers.

Without a commercial product base, real-world evidence flywheel, or partner ecosystem that compounds with scale, network effects remain absent.

Relative to peers with large patient datasets or integrated treatment ecosystems, IMMP appears structurally disadvantaged on this moat dimension.

Cost Advantage

The negative ROIC and ROCE suggest IMMP is not operating with a cost structure that converts into superior unit economics versus peers.

The very high cash conversion cycle indicates weak working-capital efficiency, which is the opposite of a durable cost advantage.

No evidence in the supplied data shows proprietary manufacturing, scale purchasing, or process advantages that would lower costs relative to other biotech developers.

Compared with larger peers that can spread R&D, regulatory, and commercialization costs across broader revenue bases, IMMP appears to lack a structural cost edge.

Efficient Scale

IMMP does not appear to operate in a naturally limited market with a protected local monopoly or capacity-constrained niche that would support efficient scale.

The absence of meaningful profitability and the lack of recurring revenue in the supplied data suggest the company has not reached a scale where fixed-cost dilution creates a moat.

Biotech development is typically contestable at the pipeline level, and IMMP’s current position does not show peer-dependent industry structure or capacity scarcity.

Relative to peers with approved products or dominant niche indications, IMMP’s scale is too small to deter entry or preserve margins.

Overall Score

IMMP’s moat is weak versus peers because the supplied data show no durable evidence of intangible assets, switching costs, network effects, cost advantage, or efficient scale, and the negative ROIC/ROCE plus poor working-capital efficiency indicate limited pricing power and retention over a 5–10 year horizon.